Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6+cetuximab (FX plus C) or FOLFIRI plus cetuximab (FF plus C): The CECOG/CORE1.2.001 trial

被引：0
|
作者：
Koza, I., Sr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wrba, F. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Vrbanec, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Ocvirk, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Ciuleanu, T. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Beslija, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Papamichael, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Messinger, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Zielinski, C. C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Brodowicz, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] NCI, Bratislava, Slovakia
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Hosp Rebro, Zagreb, Croatia
[4] Inst Oncol, Ljubljana, Slovenia
[5] Univ Med Cluj Napoca, Cluj Napoca, Romania
[6] Univ Sarajevo, Ctr Clin, Sarajevo 71000, Bosnia & Herceg
[7] Bank Cyprus Oncol Ctr, Nicosia, Cyprus
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4055
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - Primary endpoint analysis of the CEBIFOX trial
    Kasper, S.
    Meiler, J.
    Knipp, H.
    Hoehler, T.
    Reimer, P.
    Steinmetz, T.
    Berger, W.
    Linden, G.
    Ting, S.
    Markus, P.
    Paul, A.
    Dechene, A.
    Kostbade, K.
    Schuler, M.
    Trarbach, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 99 - 100
  • [32] Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study
    Tejpar, Sabine
    Lenz, Heinz-Josef
    Koehne, Claus-Henning
    Heinemann, Volker
    Ciardiello, Fortunato
    Esser, Regina
    Beier, Frank
    Stroh, Christopher
    Duecker, Klaus
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [33] Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hohler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Reis, Henning
    Markus, Peter
    Paul, Andreas
    Dechene, Alexander
    Schumacher, Brigitte
    Kostbade, Karina
    Virchow, Isabel
    Ting, Saskia
    Worm, Karl
    Schmid, Kurt W.
    Herold, Thomas
    Wiesweg, Marcel
    Schuler, Martin
    Trarbach, Tanja
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 236 - +
  • [34] Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).
    Nixon, Andrew B.
    Sibley, Alexander
    Hatch, Ace Joseph
    Liu, Yingmiao
    Jiang, Chen
    Mulkey, Flora
    Starr, Mark D.
    Brady, John C.
    Niedzwiecki, Donna
    Innocenti, Federico
    Venook, Alan P.
    Hochster, Howard S.
    Lenz, Heinz-Josef
    O'Neil, Bert H.
    Owzar, Kouros
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] CORRELATION BETWEEN IGF1R AND CMET EXPRESSION AND OUTCOME OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH CETUXIMAB PLUS CHEMOTHERAPY
    Di Salvatore, M.
    Inno, A.
    Orlandi, A.
    Martini, M.
    Cerchiaro, E.
    Bagala, C.
    Larocca, L. M.
    Cassano, A.
    Astone, A.
    Barone, C.
    CANCER TREATMENT REVIEWS, 2010, 36 : S95 - S96
  • [36] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] KRAS wild-type status in patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 regimen as the second/third-line setting: in comparison with the first-line setting
    Wang, J. -Y.
    Lin, S. -R.
    VIRCHOWS ARCHIV, 2011, 459 : S22 - S22
  • [38] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Christian
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Hielscher, Joerg
    Scholz, Michael
    Mueller, Sebastian
    Link, Hartmut
    Niederle, Norbert
    Rost, Andreas
    Hoeffkes, Heinz-Gert
    Moehler, Markus
    Lindig, Reinhard U.
    Modest, Dominik P.
    Rossius, Lisa
    Kirchner, Thomas
    Jung, Andreas
    Stintzing, Sebastian
    LANCET ONCOLOGY, 2014, 15 (10): : 1065 - 1075
  • [39] Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Hill, Andrew G.
    Findlay, Michael
    Burge, Matthew
    Jackson, Christopher
    Garcia Alfonso, Pilar
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    DiBartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana
    McCall, Bruce
    Penuel, Elicia
    Pirzkall, Andrea
    Tabernero, Josep
    CANCER RESEARCH, 2015, 75
  • [40] KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy
    Sharma, Neelesh
    Saifo, Maher
    Tamaskar, Ila R.
    Bhuvaneswari, Ramkumar
    Mashtare, Terry
    Fakih, Marwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 1 (02) : 90 - 96
12345